These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8272117)

  • 21. Persistent parkinsonism and tardive dyskinesia induced by clebopride.
    Jiménez-Jiménez FJ; Cabrera-Valdivia F; Ayuso-Peralta L; Tejeiro J; Vaquero A; García-Albea E
    Mov Disord; 1993 Apr; 8(2):246-7. PubMed ID: 8474508
    [No Abstract]   [Full Text] [Related]  

  • 22. Tardive dyskinesia.
    Ehrensing RH
    Arch Intern Med; 1978 Aug; 138(8):1261-4. PubMed ID: 677982
    [No Abstract]   [Full Text] [Related]  

  • 23. Risperidone-induced tardive dyskinesia and parkinsonism.
    Gwinn KA; Caviness JN
    Mov Disord; 1997 Jan; 12(1):119-21. PubMed ID: 8990067
    [No Abstract]   [Full Text] [Related]  

  • 24. Life-threatening tardive dyskinesia.
    Chiu HF; Chung DW; Wing YK; Wong CK
    Br J Clin Pract; 1996; 50(3):175-6. PubMed ID: 8733342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia.
    Cortese L; Caligiuri MP; Williams R; Schieldrop P; Manchanda R; Malla A; Harricharan R
    J Clin Psychopharmacol; 2008 Feb; 28(1):69-73. PubMed ID: 18204344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of amantadine (Viregyt-K) on extrapyramidal symptoms of parkinsonian patients.
    Boczán G
    Ther Hung; 1974; 22(4):147-53. PubMed ID: 4465958
    [No Abstract]   [Full Text] [Related]  

  • 27. Parkinsonism and tardive dyskinesia after chronic use of clebopride.
    Sempere AP; Duarte J; Palomares JM; Coria F; Clavería LE
    Mov Disord; 1994 Jan; 9(1):114-5. PubMed ID: 8166880
    [No Abstract]   [Full Text] [Related]  

  • 28. Drug-induced extrapyramidal symptoms.
    Rainier-Pope CR
    S Afr Med J; 1979 Jun; 55(27):1104. PubMed ID: 483093
    [No Abstract]   [Full Text] [Related]  

  • 29. Tardive dyskinesia, mild drug-induced dyskinesia, and drug-induced parkinsonism: risk factors and topographic distribution.
    Akbostanci MC; Atbaşoğlu EC; Balaban H
    Acta Neurol Belg; 1999 Sep; 99(3):176-81. PubMed ID: 10544725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extrapyramidal Reactions Associated with Serotonergic Antidepressants.
    Hawthorne JM; Caley CF
    Ann Pharmacother; 2015 Oct; 49(10):1136-52. PubMed ID: 26185277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes.
    Rich SS; Friedman JH; Ott BR
    J Clin Psychiatry; 1995 Dec; 56(12):556-9. PubMed ID: 8530331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigating levodopa-induced dyskinesias in the parkinsonian primate.
    Langston JW; Quik M; Petzinger G; Jakowec M; Di Monte DA
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S79-89. PubMed ID: 10762135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discharge rate of substantia nigra pars reticulata neurons is reduced in non-parkinsonian monkeys with apomorphine-induced orofacial dyskinesia.
    Nevet A; Morris G; Saban G; Fainstein N; Bergman H
    J Neurophysiol; 2004 Oct; 92(4):1973-81. PubMed ID: 15115785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Analysis and nursing care of extrapyramidal reactions caused by antipsychotics in 75 cases].
    Li NP
    Zhonghua Hu Li Za Zhi; 1997 Feb; 32(2):84-6. PubMed ID: 9369564
    [No Abstract]   [Full Text] [Related]  

  • 35. Tardive dystonia: treatment with trihexyphenidyl.
    Wolf ME; Koller WC
    J Clin Psychopharmacol; 1985 Aug; 5(4):247-8. PubMed ID: 2862167
    [No Abstract]   [Full Text] [Related]  

  • 36. Physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia.
    Vitek JL; Giroux M
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S131-40. PubMed ID: 10762140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuronal basis of neuroleptic-induced extrapyramidal side effects.
    Ossowska K
    Pol J Pharmacol; 2002; 54(4):299-312. PubMed ID: 12523484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute organophosphate poisoning presenting with choreo-athetosis.
    Joubert J; Joubert PH; van der Spuy M; van Graan E
    J Toxicol Clin Toxicol; 1984; 22(2):187-91. PubMed ID: 6209420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralization of extrapyramidal side-effects with Methixene.
    Maller O; Heller S
    Dis Nerv Syst; 1971 Jun; 32(6):409-15. PubMed ID: 5570695
    [No Abstract]   [Full Text] [Related]  

  • 40. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
    Blanchet PJ; Grondin R; Bédard PJ
    Mov Disord; 1996 Jan; 11(1):91-4. PubMed ID: 8771074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.